FHTX - CIK 0001822462
Foghorn Therapeutics Inc. (FHTX) reported net income of -$74.28M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$74.28M | +14.2% |
| FY 2024 | -$86.62M | +12.0% |
| FY 2023 | -$98.43M | +9.6% |
| FY 2022 | -$108.88M | -7.5% |
| FY 2021 | -$101.32M | -47.3% |
| FY 2020 | -$68.80M | -34.6% |
| FY 2019 | -$51.13M | - |
Foghorn Therapeutics Inc. (FHTX) reported net income of -$74.28M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Foghorn Therapeutics Inc.'s net income declined from -$51.13M to -$74.28M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.